INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Not for submission under 37 CFR 1 99)

Application Number		10511409		
Filing Date		2004-10-13		
First Named Inventor Xia Xi		u, et al.		
Art Unit		1743		
Examiner Name Not Y		et Assigned		
Attorney Docket Number		NIHA-0249/E-103-2002		

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	Name of Pat of cited Docu	entee or Applicant iment	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1									
If you wis	h to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	Lease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pat of cited Docu	entee or Applicant Iment	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
/K.M./	1	20050181514	A1	2005-08	3-18	Xu, et al.				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d butto	on.	
				FOREIG	GN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
/K.M./	1	WO03089921	wo		A1	2003-10-30	The Government o United States of Ar			
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	butto	า	
			NON	I-PATEI	NT LITE	RATURE DO	CUMENTS			
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10511409		
Filing Date		2004-10-13		
First Named Inventor Xia Xi		u, et al.		
Art Unit		1743		
Examiner Name Not Y		et Assigned		
Attament Dealest Northern		NILLA 0240/E 102 2002		

/K.M./	1	ADLERCRUETZ, H., ET Al, "Estrogen metabolism and excretion in oriental and caucasian women," J. Natl. Cancer Inst., 1994, 86(14), 1078-1082	
	2	ADLERCREUTZ, H., ET AL., "An isotope dilution gas chromatographic-mass spectrometric method for the simulataneous assay of estrogens and phytoestrogens in urine," J. Steroid Biochem. & Mol. Biol., 2004, 92(5), 399-411	
	3	ANARI, ET AL., "Derivatization of ethinylestradiol with dansyl chloride to enhance electrospray ionization: application in trace analysis of ethinylestradiol in rhesus monkey plasma," Anal. Chem., 2002, 74, 4136-4144	
	4	Answers.com, "Blood plasma: definition and much more for answers.com," http://www.answers.com/topic/blood- plasma, downloaded from the internet on November 11, 2005, 4 pages	
	5	Ball, P., et al., "Radioimmunoassay of 2-hydroxyesterone and 2-methoxyestrone in human urine," Steroids, 1979, 33 (5), 563-576	
	6	BANKS, J.T., ET AL., "Thermal and photochemical fragmentation of a,a-dialkoxybenzyl radicals:a comparison of the thermal reactions with laser induced fragmentations by using laser flash and laser-jet photolyses," J. Am. Chem. Soc., 1993, 115, 2473-2477	
	7	BANWELL, M.G., ET AL., "Generation and solution-phase behaviour of some 2-halogeno-1,3-ring-fused cyclopropenes," J. Chem. Soc. Perkin Trans. 1, 1993, 945-963	
	8	BEATSON, G.T., "On the treatment of inoperable cases of carcinoma of the amma: suggestions for a new method of treatment, with illustrative cases," Lancet, 1896, 2, 104-107	
	9	BRADLOW, H.L., ET AL., "Application of an improved ELISA assay to the analysis of urinary estrogen metabolites," Steroids, 1998, 63, 406-413	
\bigvee	10	CAVALIERI, E.L., ET AL., "Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators," proc. Natl. Acad. Sci. USA, 1997, 94, 10937-10942	
/K.M./	11	CLEMONS, M., ET AL., "Estrogen and the risk of breast cancer," N. Engl. J. Med., 2001, 344, 276-285	

INFORMATION DISCLOSURE

(Not for submission under 37 CFR 1.99)

Application Number		10511409		
Filing Date		2004-10-13		
First Named Inventor Xia Xi		u, et al.		
Art Unit		1743		
Examiner Name Not Y		et Assigned		
Attorney Docket Number		NIHA-0249/F-103-2002		

/K.M./	12	COLDITZ, G.A., "Relationship between estrogen levels, use of hormone replacement thereapy, and breast cancer," J. Natl. Cancer Inst., 1998, 90(11), 814-823	
	13	DUMITRESCU, R.G., ET AL., "Understanding breast cancer risk-where do we stand in 2005?," J. Cell Mol. Med., 2005, 9(1), 208-221	
	14	EMONS, G., ET AL., "Radioimmunoassay for 4-hydroxyoestrone in human urine," Acta Endocinology, 1981, 97, 251-257	
	15	FENN, J.B., ET AL., "Electrospray ionization-principles and practice," Mass Spectrom. Rev., 1990, 9, 37-70	
	16	FISHMAN, J., ET Al., "Biological properties of 16 a-hydroxyestrone: implications in estrogen physiology and pathophysiology," J. Clin. Endocrinol. Metab., 1980, 51(3), 611-615	
	17	GETENS, G., ET AL., "Nanotechnology in bio/clinical analysis," J. Chromatogr. B, 2000, 739, 139-150	
	18	KAAKS, R., "Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies," IARC Sci. Publ., 2001, 154, 149-162	
	19	KEY, T.J.A., ET AL., "A prospective study of urinary oestrogen excretion and breast cancer risk," Br. J. of Cancer, 1996, 73, 1615-1619	
	20	KLUG, T.L., ET AL., "Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine," Steroids, 1994, 59, 648-655	
	21	LEE, A.J., ET AL., "Characterization of the NADPH-dependent metabolism of 17B-estradol to multiple metabolities by human liver microsomomes and selectively expressed human cytochrome P450 3A4 and 3A5," J. Pharmacology & Experimental Therapeutics, 2001, 298(2), 420-432	
/K.M./	22	MAKELA, S.K., ET AL., "Nonspecificity of a direct 17 a hydroxyprogesterone radioimmunoassay kit when used with samples for neonates," Clin. Chem., 1988, 34(10), 2070-2075	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10511409		
iling Date		2004-10-13		
irst Named Inventor Xia Xu		u, et al.		
Art Unit		1743		
Examiner Name Not Y		et Assigned		
Manney Dealest Niverban		NULLA 0040/E 400 0000		

/K.M./	23	McGUINNES, B.J., ET AL., "Radioimmunoassay of 2-hydroxyestrone in urine," Clin. Chem., 1994, 40, 80-85	
	24	NELSON, ET AL., "Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma," Clin. Chem., 2004, 50(2), 373-384	
	25	NUMAZAWA, M., ET AL., "Radioimmunoassay of 2-hydroxyesterone using antisera raised against antigenic complexes obtained by convenient methods," Chem. Pharm. Bull., 1989, 37, 1561-1563	
	26	PIKE, M.C., ET AL., "Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk," Epidemiol. Rev., 1993, 15, 17-35	
	27	SHIMADA, K., ET AL., "Studies on steroids: CLXV. Determination of isomeric catechol estrogens in pregnancy urine by high performance liquid chromatography with electrochemical detection," J. Chromatogr., 1981, 223, 33-39	
	28	SHIMADA, K., ET AL., "Studies on steroids: CCXXIX. Separation and characterization of catechol oestrogen glucuronides in urine of pregnant woman by high-performance liquid chromatography," J. Chromatogr., 1987, 400, 215-221	
	29	SHOU, ET AL., "Development and validation of a high-sensitivity liquid chromatography/tandem mass spectrometry (LC/MS/MS) method with chemical derivatization for the determination of ethinyl estradiol in human plasma," Biomed. Chromatogr., 2004, 18(7), 414-421	
	30	SUZUKI, E., ET AL., "Assay of enzymic O-methylation of catechol oestrogens by high-performance liquid chromatography with coulometric detection," J. Chromatogr., 1993, 617, 221-225	
	31	TODOROVIC, R., ET AL., "Analysis of potential biomarkers of estrogen-initiated cancer in the urine of syrian golden hamsters treated with 4-hydroxyestradiol," Carcinogenesis, 2001, 22, 905-911	
\bigvee	32	TONIOLO, P. G., ET AL., "A prospective study of endogenous estrogens and breast cancer in postmenopausal women," J. of the Natl. Cancer Inst., 1995, 87(3), 190-197	
/K.M./	33	TRAVIS, R.C., ET AL., "Oestrogen exposure and breast cancer risk," Breast Cancer Res., 2003, 5, 239-247	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10511409		
Filing Date		2004-10-13		
First Named Inventor Xia Xi		u, et al.		
Art Unit		1743		
Examiner Name Not Y		et Assigned		
Attorney Docket Number		NIHA-0249/F-103-2002		

/K.M./	34	WONG, T., ET AL., "identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioirmunoassay," Clin. Chem., 1992, 38(9), 1830-1837								
/K.M.	35	WUDY, S.A., "Determination of dehydroepiandrosterone sulfate in human plasma by gas chromatography/mass spectrometry using a deuterated internal standard: a method suitable for routine clinical use," Horm. Res., 1993, 39, 235-240								
/K.M.	36	XU, X., ET AL., "Analysis of fifteen estrogen metabolites using packed column supercritical fluid chromatography mass spectrometry," Anal. Chem., 2006, 78, 1553-1558								
/K.M./	37	XU, X., ET AL., "Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry," Anal. Chem., 2005, 77, 6646-6654								
/K.M./	38	YAGER, J.D., ET AL., "Molecular mechanisms of estrogen carcinogenesis," Annu. Rev. Pharmacol. Toxicol., 1996, 36, 203-232								
/K.M./	39	ZHANG, ET AL., "Quantitation of 17 a-ethylestradiol in aquatic samples using liquid-liquid phase extraction, dansyl derivatization and liquid chromatography/positive electrospray tandem mass spectrometry." Rapid Commun. Mass Spectrom., 2004, 18(22), 2739-2742								
If you wis	h to a	d additional non-patent literature document citation information please click the Add button								
		EXAMINER SIGNATURE								
Examiner	Signa	ture /Keri Moss/ Date Considered 02/25/2009								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.